Linked Life Data

2107589

Source:http://linkedlifedata.com/resource/pubmed/id/2107589

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1990-4-26
pubmed:abstractText
Patients with fibrosing alveolitis have active inflammation within their lung interstitium. Previous studies have focused on the humoral (immune complex) driven processes. In this study increased pulmonary gamma interferon production has been evaluated. Bronchoalveolar lavage cells were obtained from 40 patients with fibrosing alveolitis, 22 with cryptogenic fibrosing alveolitis, and 18 with connective tissue disease associated (CTD) fibrosing alveolitis. Increased gamma interferon production was seen in 12 (30%) patients and was similar in the two study groups. Up to 512 units/10(6) cells were released over 24 hours, showing that the amounts of gamma interferon released could be as large as those seen in other pulmonary diseases associated with active cellular immune processes, such as sarcoidosis. Spontaneous gamma interferon production was related to increased serum concentrations of IgG and IgM but not to serum IgA, antinuclear antibody, or rheumatoid factor titres. There was no relation between gamma interferon production and pulmonary uptake of gallium-67 citrate. The ratio of helper-inducer (Leu-3) to suppressor-cytotoxic (Leu-2) cells in bronchoalveolar lavage fluid was similar in the two study groups and was similar in patients whose cells produced gamma interferon and those whose cells did not. These data suggest that gamma interferon is released in the lungs of a proportion of individuals with cryptogenic fibrosing alveolitis and CTD-fibrosing alveolitis, suggesting a role for this cytokine in mediating these diseases.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-146160, http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-2408524, http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-2465144, http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-2956939, http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-3017641, http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-3166918, http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-3305583, http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-3463286, http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-3923038, http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-6093663, http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-6189434, http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-6361560, http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-6446683, http://linkedlifedata.com/resource/pubmed/commentcorrection/2107589-7434282
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0040-6376
pubmed:author
pubmed:issnType
Print
pubmed:volume
45
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
105-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Pulmonary gamma interferon production in patients with fibrosing alveolitis.
pubmed:affiliation
Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands.
pubmed:publicationType
Journal Article